Breaking News: Statins, the cholesterol-lowering medications, are beneficial for people with type 2 diabetes, even if they're considered low-risk. This is a game-changer! A recent study suggests that rigid risk assessments might not be necessary when deciding if statins are right for you. But what does this mean for you? Let's dive in.
Published on January 5, 2026, a target trial emulation study revealed that statins offer safety and advantages for adults with type 2 diabetes, regardless of their estimated 10-year cardiovascular disease (CVD) risk.
Researchers, led by Dr. Vincent Ka Chun Yan and Dr. Joseph Edgar Blais from the University of Hong Kong, discovered significant long-term reductions in overall mortality and major CVD events, even among the lowest-risk patients who took statins. The benefits appeared to increase with higher baseline QRISK3 predicted risk. The study, published in the Annals of Internal Medicine, also found that statin use didn't significantly increase the risk of myopathy (muscle issues) or liver dysfunction. The study did not explore potential impacts on glucose control.
Dr. Eric Yuk Fai Wan, the senior author, shared that the balance of risks and benefits strongly favors statin use. He was surprised by the consistent benefit even in low-risk groups, especially those with elevated LDL cholesterol. He also found the safety profile reassuring, with no significant liver harm and only a slight increase in muscle-related issues.
But here's where it gets controversial... Current international guidelines on primary prevention for type 2 diabetes patients vary when it comes to the 10-year CVD risk thresholds for starting statins. Dr. Wan noted that there's uncertainty about using these medications when the baseline risk is low, as previous studies often excluded younger or low-risk patients and had short follow-up periods.
To fill this gap, the researchers examined outcomes associated with statin use across the risk spectrum. They analyzed primary care data from the United Kingdom, including patients aged 25 to 84 years who were diagnosed with type 2 diabetes between 2005 and 2016 and had no prior history of statin use, coronary artery disease, or other related conditions. Patients were categorized into four groups based on their predicted 10-year CVD risk using the QRISK3 tool: low (< 10%), intermediate (10% to 19%), high (20% to 29%), and very high (≥ 30%).
After matching, the analysis included 64,589 eligible person-trials in the low-risk group, 117,630 in the intermediate-risk group, 101,262 in the high-risk group, and 135,067 in the very-high-risk group. Statins were initiated in 20% of the patients. The average age was 44 years in the low-risk group, compared to 68 years in the very-high-risk group. Through a median follow-up of 81 months for statin users and 75 months for non-users, statin use was linked to reduced risks of all-cause mortality and major CVD events across all risk levels.
Here's a quick look at the results:
- All-Cause Mortality: The risk ratio for the low-risk group was 0.80 (95% CI: 0.67-0.97), meaning a reduction in risk.
- Major CVD Events: The risk ratio for the low-risk group was 0.78 (95% CI: 0.66-0.91), also showing a reduction in risk.
There were no significant differences in myopathy or liver dysfunction risks based on statin use. The findings from the per-protocol (PP) analysis largely matched the intention-to-treat (ITT) results. In both ITT and PP analyses, the reductions in mortality and major CVD events in the low-risk group seemed to be limited to patients with a baseline LDL-cholesterol level ≥ 2.6 mmol/L (about 101 mg/dL) or a baseline non-HDL cholesterol level ≥ 3.4 mmol/L (about 131 mg/dL).
Dr. Wan suggests that clinicians should consider statins for most adults with type 2 diabetes, especially if LDL cholesterol is elevated. He emphasized the importance of long-term adherence, as the benefits become clear after several years. He believes these results support a more inclusive approach to statin therapy and may help align international guidelines. They provide strong evidence for lowering or removing strict risk thresholds in favor of individualized decisions.
What are your thoughts? Do you agree with the findings? Share your opinions in the comments below!
